Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016, provides an overview of the Haemophilus influenzae Type B Infections (Infectious Disease) pipeline landscape. Haemophilus influenzae type B (Hib) is a bacterium that causes a life-threatening infection that can lead to serious illness, especially in children. Symptoms include severe headache, stiff neck, convulsions or seizures, severe drowsiness, difficulty waking up, loss of consciousness or difficulty with breathing. Predisposing factors include age and weakened immune system. Treatment includes antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Haemophilus influenzae Type B Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 4, 2, 3, 1 and 6 respectively for Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively for Haemophilus influenzae Type B Infections. Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Haemophilus influenzae Type B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Haemophilus influenzae Type B Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Haemophilus influenzae Type B Infections Overview 8 Therapeutics Development 9 Pipeline Products for Haemophilus influenzae Type B Infections - Overview 9 Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis 10 Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies 11 Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes 12 Haemophilus influenzae Type B Infections - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Haemophilus influenzae Type B Infections - Products under Development by Companies 16 Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes 18 Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development 19 Beijing Minhai Biotechnology Co., Ltd 19 Biological E. Limited 20 Daiichi Sankyo Company, Limited 21 Indian Immunologicals Limited 22 Kaketsuken K.K. 23 LG Life Science LTD. 24 Panacea Biotec Limited 25 Sanofi Pasteur SA 26 Sinovac Biotech Ltd. 27 Zydus Cadila Healthcare Limited 28 Haemophilus influenzae Type B Infections - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 (meningococcal + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Eupenta - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 haemophilus influenzae B vaccine - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Haemophilus influenzae B vaccine - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Haemophilus influenzae B vaccine - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 hemophilus influenza [serotype B] vaccine - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 KD-370 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 LT-Hib - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 NU-300 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 VN-0105 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Haemophilus influenzae Type B Infections - Dormant Projects 59 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 61 Disclaimer 62
List of Tables
Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2016 9 Number of Products under Development for Haemophilus influenzae Type B Infections - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Products under Investigation by Universities/Institutes, H2 2016 18 Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 19 Haemophilus influenzae Type B Infections - Pipeline by Biological E. Limited, H2 2016 20 Haemophilus influenzae Type B Infections - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 21 Haemophilus influenzae Type B Infections - Pipeline by Indian Immunologicals Limited, H2 2016 22 Haemophilus influenzae Type B Infections - Pipeline by Kaketsuken K.K., H2 2016 23 Haemophilus influenzae Type B Infections - Pipeline by LG Life Science LTD., H2 2016 24 Haemophilus influenzae Type B Infections - Pipeline by Panacea Biotec Limited, H2 2016 25 Haemophilus influenzae Type B Infections - Pipeline by Sanofi Pasteur SA, H2 2016 26 Haemophilus influenzae Type B Infections - Pipeline by Sinovac Biotech Ltd., H2 2016 27 Haemophilus influenzae Type B Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 28 Assessment by Monotherapy Products, H2 2016 29 Assessment by Combination Products, H2 2016 30 Number of Products by Stage and Target, H2 2016 32 Number of Products by Stage and Route of Administration, H2 2016 34 Number of Products by Stage and Molecule Type, H2 2016 36 Haemophilus influenzae Type B Infections - Dormant Projects, H2 2016 59 Haemophilus influenzae Type B Infections - Dormant Projects (Contd..1), H2 2016 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.